Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting

Curis Inc CRIS presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting.
The TakeAim Lymphoma Phase 1/2 study is investigating emavusertib as monotherapy and in combination with ibrutinib in patients with R/R hematologic malignancies.
The combination appeared to be well tolerated, with no dose-limiting toxicities (DLTs) at 200mg of emavusertib.
Two DLTs were observed at 300mg (stomatitis and syncope).
8 of 9 evaluable patients experienced a reduction in tumor burden.
Related: After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study.
The TakeAim Leukemia study is a Phase 1/2 study examining emavusertib use as monotherapy and in combination with azacitidine or venetoclax in patients with R/R AML or high-risk MDS.
Emavusertib was well-tolerated across multiple dose levels, and no dose-limiting myelosuppression was observed.
In patients with spliceosome-mutated R/R AML, CR/CRh rate of 40% (2 out of 5 patients) (CRh=complete response with partial hematologic recovery).
Consistent tumor burden reduction was observed. 4 out of 5 patients achieved blast reduction, three by ≥ 50%.
In patients with spliceosome-mutated R/R MDS, the objective response rate was 57%.
In patients with FLT3-mutated R/R AML, the CR rate was 33%.
Price Action: CRIS shares are up 14.9% at $1.08 during the premarket session on the last check Monday.